Clinical effectiveness of tigecycline in combination therapy against nosocomial pneumonia caused by carbapenem-resistant Gram-negative bacteria (CR-GNB) in intensive care units: a retrospective multi-centre observational study
Main finding · All-cause mortalityResult — go to the resultAdjusted hazard ratio 0.69 95% CI 0.47–0.99Authors' conclusion
In this retrospective observational study that included ICU-admitted patients with nosocomial pneumonia caused by tigecycline-susceptible CR-GNB, mostly CRAB, tigecycline as part of a combination treatment regimen was associated with lower clinical failure and all-cause mortality rates.
Study context
- Population
- Intensive care unit (ICU)-admitted patients with nosocomial pneumonia caused by CR-GNB (>80% CR-Acinetobacter baumannii (CRAB))
- Participants
- 395 patients
- Exposure
- Tigecycline vs Without tigecycline
- Tigecyclinen = 148
- Without tigecyclinen = 247reference
- Outcome
- All-cause mortality
- Follow-up
- Day 28
Methodological detailsmulticentre, propensity-score matched
- Multicentre
- Propensity-score matched
Main finding
As reported in the abstract
Adjusted hazard ratio
0.69
95% CI 0.47–0.99
By group
Observational data: associations, not effects.
Further findings
All-cause mortality (PS-matched cohort, 102 pairs) · day 28 · propensity-score matched cohort
P < 0.001
Clinical failure (PS-matched cohort, 102 pairs) · day 28 · propensity-score matched cohort
P = 0.017
| Outcome | Estimate | |
|---|---|---|
| All-cause mortality (PS-matched cohort, 102 pairs) · day 28Multivariate · propensity-score matched cohort | aHR 0.47 (95% CI 0.30–0.74) | |
| Clinical failure (PS-matched cohort, 102 pairs) · day 28Multivariate · propensity-score matched cohort | aOR 0.52 (95% CI 0.28–0.95) | |
| 0.20.5125Ratio (log scale) |
Survival by companion agent (subgroup, Kaplan-Meier)
- Benefit of tigecycline added to colistin-included regimen (log rank p)
- 0.005
- Benefit of tigecycline added to carbapenem-included regimen (log rank p)
- 0.007
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →